New vaccine against rift valley fever shows promise in early trial
NCT ID NCT06799234
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new vaccine called ChAdOx1 RVF against Rift Valley fever in 240 healthy adults in Kenya. Participants receive either one or two doses of the vaccine or a rabies vaccine as a control. Researchers will check if the vaccine triggers a strong immune response and monitor for any side effects over 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ChAdOx1 RVF vaccine
- What this could lead to
- If successful, this could lead to a safe and effective vaccine to prevent Rift Valley fever, a serious viral disease.
- What could go wrong
- This is a Phase 2 trial with only 240 participants, so results may not apply to larger populations. The vaccine may not produce a strong enough immune response or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIFT VALLEY FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
KEMRI-Wellcome Trust Research Programme
Kilifi, Coast, 254, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.